Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07271420

Enrollment

Registered

2025-12-09

Start date

2020-01-01

Completion date

2027-06-30

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Kidney Disease (ESRD), Hypertension, Peritoneal Dialysis

Keywords

Hypertension, Thiazides diuretics, End stage kidney disease, Peritoneal dialysis

Brief summary

To evaluate the blood pressure lowering effects of thiazide diuretics in patients on peritoneal dialysis

Detailed description

This prospective, single-center treatment-withdrawal crossover study enrolled 10 patients on chronic peritoneal dialysis (PD) and uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg). Following written informed consent, participants entered the treatment arm, receiving oral hydrochlorothiazide once daily on top of their standard of treatment for 90 days. This was followed by a 14-day washout period, after which participants entered a 90-day control period.

Interventions

DRUGHydrochlorothiazide 25mg once per day

Thiazides diuretics

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Following written informed consent, participants entered the treatment arm, receiving oral hydrochlorothiazide once daily on top of their standard of treatment for 90 days. This was followed by a 14-day washout period, after which participants entered a 90-day control period.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg)

Exclusion criteria

* Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months

Design outcomes

Primary

Measure	Time frame
Change in systolic and diastolic blood pressure	90 days

Secondary

Measure	Time frame
Changes in body weight	90 days
Changes in body composition measured by bio impedance spectroscopy	90 days
Change in urinary fractional excretion of sodium	90 days

Countries

Hong Kong

Contacts

Primary ContactGordon Chan, MD, MRCP

cck295@ha.org.hk0085235052211

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026